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Introduction
Increasing number of studies is now devoted to immu-
notherapy of cancer. We evaluated the clinical benefit of
hepcortespenlisimut‐L (V5) – an oral therapeutic vac-
cine designated by the US FDA as an orphan drug for
treatment of hepatocellular carcinoma (HCC).
Patients
Open-label Phase II trial (NCT02256514) is currently
underway, which by now has enrolled 75 patients with
advanced HCC, consisting of 29 (38.7%) females and 46
(61.3%) males with median age 60 years (Mean 61.6±8.1).
Out of these 32 (42.7%) had hepatitis B and 43 (57.3%)
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hepatitis C infections, including 8 (10.7%) with dual
infection, 4 (5.3%) negative for both viruses and 5 (6.7%)
without established viral diagnosis.
Results
After median 2 months of daily dose of V5 pill, 50 out
75 patients had experienced decline in serum levels of
tumor marker, alphafetoprotein, (66.7%; P=0.008 by
Wilcoxon Signed Rank test). Baseline median AFP levels
were 245.2 IU/ml (Mean 4,233; Range 7.2-92,407; 95%
CI 1,186-7,280) and post-treatment values were 102.3
IU/ml (Mean 2,539; Range 0.9-54,478; 95% CI 503-
4,575). The decrease in AFP was correlated either with
tumor clearance or regression on CT scans. The median
overall survival time could not be established since 70 out
75 (93.3%) are still alive after median follow-up of
10 months (Mean 13; Range 5-57; 95% CI 10.7-15.2). The
first patient in this study received immunotherapy 57
months ago and is doing well without any trace of lesions.
None of the patients experienced any adverse effects, con-
trary their liver function tests had improved.
Conclusion
The results indicate that hepcortespenlisimut-L is safe,
effective and fast-acting immunomodulatory interven-
tion for HCC. The Phase III randomized, double-blind,
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